- ScaleUp Bio announces initial customer partnerships from the USA, Australia, and Asia.
- The company is nearing the completion of Singapore’s first dedicated food-grade precision fermentation facilities.
- Collaboration with Australia’s Nourish Ingredients aims to bring sustainable fermentation-based specialty fats to Asia.
- Letters of Intent signed with USA’s C16 Biosciences, Malaysia’s Ultimeat, and Singapore’s Allium Bio.
- ScaleUp Bio’s unique CDMO model fills a critical gap in scaling up food tech innovations.
Global Partnerships for Sustainable Food
ScaleUp Bio has entered into a collaboration agreement with Australia’s Nourish Ingredients to support its growth strategy in Asia. Additionally, the company has signed Letters of Intent with C16 Biosciences from the USA, Ultimeat from Malaysia, and Singapore’s Allium Bio. These companies are leveraging the company’s expertise to develop sustainably produced ingredients for novel foods.
Francisco Codoñer, CEO of ScaleUp Bio, expressed enthusiasm about the partnerships, stating, “These companies recognize the significant growth opportunities for novel foods across Asia and understand the unique advantages ScaleUp Bio offers.”
A Joint Venture with a Unique Model
Established in Q3 2022 as a joint venture between global nutrition leader ADM and Singapore’s investment giant Temasek’s wholly-owned company Nurasa, ScaleUp Bio aims to bridge the scaling-up gaps faced by global food tech innovators. The company operates on a clear, fee-for-service CDMO business model, offering a mix of facilities, expertise, and essential services.
Specialized Collaboration with Nourish Ingredients
Nourish Ingredients, founded in Australia in 2019, specializes in creating animal-free fats that enhance the taste of plant proteins. The company has chosen Singapore as its strategic hub for scaling production. The collaboration with the Singaporean company will provide Nourish Ingredients with 10,000 liters of fermentation capacity and 100 liters of thermal processing to scale the production of specialty fats.
Letters of Intent Signal Robust Interest
ScaleUp Bio has received initial Letters of Intent from companies like C16 Biosciences, which aims to produce sustainable alternatives to palm oil, and Ultimeat, focusing on plant-based meat alternatives. These Letters of Intent allow these companies to reserve blocks of ScaleUp Bio’s mission-critical facilities, aiding in their business planning.
Pioneering Facilities in Singapore
The company is in the final stages of completing Singapore’s first dedicated food-grade precision fermentation facilities. These facilities will support research and development as well as pilot-stage manufacturing. The company expects full operations to commence in early 2024.
With these developments, ScaleUp Bio is positioning itself as a key player in the global food tech industry, offering end-to-end CDMO services to innovators worldwide.
Image provided by ScaleUp Bio